Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

How to Calculate CJC-1295 No DAC & Ipamorelin Concentration

How to Calculate CJC-1295 No DAC & Ipamorelin Concentration Most peptide reconstitution errors aren't caused by contamination, sterility failures, or poor injection technique. They're caused by miscalculating concentration before the first dose is ever drawn.

By Recovery & Performance Peptides Editorial Team

How to Calculate CJC-1295 No DAC & Ipamorelin Concentration

Most peptide reconstitution errors aren't caused by contamination, sterility failures, or poor injection technique. They're caused by miscalculating concentration before the first dose is ever drawn. A researcher who assumes '5mg peptide in 2mL bacteriostatic water equals 2.5mg/mL' without accounting for lyophilized mass accuracy, reconstitution dilution factors, or dosing syringe precision will generate inconsistent results across every subsequent experiment. The gap between published research protocols and reproducible lab outcomes comes down to three calculation errors most guides never address.

Our team has worked with research-grade peptides across hundreds of protocols. The pattern is consistent: calculation errors at the reconstitution stage cascade through every dose, creating variance that compromises study integrity long before data analysis begins.

How do you calculate CJC-1295 No DAC & Ipamorelin concentration after reconstitution?

To calculate CJC-1295 No DAC & Ipamorelin concentration, divide the peptide mass (in milligrams or micrograms) by the total reconstitution volume (in milliliters). For example: 5mg peptide powder reconstituted in 2mL bacteriostatic water yields 2.5mg/mL concentration. Always verify lyophilized peptide mass using supplier certificates of analysis. Vial labels indicate nominal mass, not actual assayed mass, which typically varies ±3–8%.

The reason concentration calculations fail isn't a lack of understanding basic division. It's the assumption that vial labels reflect precise peptide content. A vial labeled '5mg CJC-1295 No DAC' contains 5mg ± manufacturer variance, which for research-grade peptides typically ranges from 92–108% of stated mass. For protocols requiring dosing precision below ±10%, that variance matters. This piece covers the exact formula researchers use to calculate peptide concentration, how to adjust for lyophilized mass variance, and what calculation mistakes negate reproducibility entirely.

Step 1: Verify Lyophilized Peptide Mass Using Certificate of Analysis (COA)

Before you calculate CJC-1295 No DAC & Ipamorelin concentration, confirm the actual peptide mass in the vial using the supplier's Certificate of Analysis (COA). Vial labels state nominal mass (e.g., '5mg'), but research-grade peptides are manufactured with batch-specific purity and mass variance. A COA provides the assayed peptide content. The percentage of the stated mass that is active peptide versus excipients, salts, or degradation products.

For example: a vial labeled '5mg CJC-1295 No DAC' with 96% purity contains 4.8mg active peptide. If you reconstitute assuming 5mg and dose accordingly, every injection delivers 96% of the intended dose. A 4% underdose that compounds across multi-week protocols. We've seen research teams dismiss COA data as 'minor variance' until dose-response curves shifted unexpectedly between batches.

Reputable peptide suppliers like Real Peptides provide batch-specific COAs with HPLC verification of purity and mass spectrometry confirmation of molecular weight. For protocols where reproducibility matters. Dose-response studies, multi-site trials, longitudinal cohort work. Using COA-adjusted mass is non-negotiable.

How to read a COA for concentration calculations:Find the 'Purity' or 'Assay' field (typically expressed as a percentage). Multiply the vial's stated mass by the purity percentage to get actual peptide mass. Example: 5mg vial × 0.96 purity = 4.8mg active peptide. Use this value in your concentration formula.

Step 2: Calculate Concentration Using the Peptide Dilution Formula

The core formula to calculate CJC-1295 No DAC & Ipamorelin concentration after reconstitution is:

Concentration (mg/mL) = Peptide Mass (mg) ÷ Reconstitution Volume (mL)

Or, for microgram precision:

Concentration (mcg/mL) = Peptide Mass (mg) × 1000 ÷ Reconstitution Volume (mL)

Example 1: A 5mg vial of CJC-1295 No DAC reconstituted with 2mL bacteriostatic water yields 2.5mg/mL or 2500mcg/mL concentration.

Example 2: A 2mg vial of Ipamorelin reconstituted with 1mL bacteriostatic water yields 2mg/mL or 2000mcg/mL concentration.

This formula assumes complete dissolution. Peptides in lyophilized form must fully dissolve in the reconstitution solvent before the solution is homogeneous. Incomplete dissolution (visible particulates, cloudy solution, or powder residue at the vial bottom) means the stated concentration is inaccurate because not all peptide mass is in solution. Gentle swirling (never shaking, which denatures peptides) for 30–60 seconds after adding bacteriostatic water ensures full reconstitution.

Dosing syringe precision matters here. Insulin syringes typically used for peptide injection are calibrated in 0.01mL (10-unit) increments. To draw a 200mcg dose from a 2000mcg/mL solution requires 0.1mL. The precision floor for most syringes. Doses below 0.05mL (50 units) introduce ±20% volumetric error, which is why reconstitution volume should be chosen to keep target doses above 0.1mL whenever possible.

Step 3: Adjust Dosing Volume Based on Target Dose and Syringe Precision

Once you've calculated concentration, the next step is determining injection volume to achieve the target dose. The formula is:

Injection Volume (mL) = Target Dose (mcg) ÷ Concentration (mcg/mL)

Example: To administer a 200mcg dose of CJC-1295 No DAC from a solution with 2500mcg/mL concentration:

200mcg ÷ 2500mcg/mL = 0.08mL (8 units on a U-100 insulin syringe)

The problem: 0.08mL is below the 0.1mL precision floor for most syringes, introducing significant volumetric error. The solution is adjusting reconstitution volume to increase injection volume into the reliable range (0.1–0.5mL).

Reconstitution volume adjustment: If your target dose consistently requires injection volumes below 0.1mL, increase reconstitution volume. For the example above, reconstituting the same 5mg vial with 3mL instead of 2mL yields 1667mcg/mL concentration, which means a 200mcg dose requires 0.12mL. Comfortably above the precision floor.

Our team has found that optimal injection volumes for U-100 syringes fall between 0.15mL and 0.4mL. Below 0.15mL, syringe calibration variance compounds. Above 0.5mL, subcutaneous injection discomfort increases due to injection site volume. Reconstitution volume should be chosen to keep target doses within this range across the protocol duration.

For combination protocols using CJC-1295 No DAC and Ipamorelin together (a common pairing in growth hormone research), calculate each peptide's concentration independently, then draw both from separate vials in a single syringe if volumes permit. Never mix peptides in the same reconstitution vial. Doing so eliminates traceability and makes dose adjustments impossible.

CJC-1295 No DAC & Ipamorelin: Peptide Concentration Comparison

CJC-1295 No DAC

2mg

1mL

2000mcg/mL

100–500mcg

0.1mL

Standard reconstitution for most protocols. Yields injection volumes in the 0.1–0.25mL range for typical dosing

5mg

2mL

2500mcg/mL

0.08mL

Common but suboptimal. Doses below 250mcg fall under 0.1mL precision floor; use 3mL reconstitution instead

Ipamorelin

200–300mcg

Most versatile for combination protocols. 1:1 volume ratio with CJC-1295 simplifies dual-peptide dosing

Same issue as CJC-1295 at this concentration. Increase to 3mL for better syringe precision at typical doses

3mL

1667mcg/mL

0.12mL

Optimal for protocols requiring doses below 250mcg. All target doses fall within 0.12–0.3mL injection volume range

Best concentration for reproducibility. Injection volumes stay above precision floor across the entire dose range

Key Takeaways

To calculate CJC-1295 No DAC & Ipamorelin concentration, divide peptide mass (in mg) by reconstitution volume (in mL). 5mg peptide in 2mL yields 2.5mg/mL or 2500mcg/mL.

Always verify actual peptide mass using the supplier's Certificate of Analysis (COA). Vial labels state nominal mass, but research-grade peptides typically contain 92–108% of stated mass depending on purity.

Reconstitution volume should be chosen to keep target injection volumes between 0.15mL and 0.4mL for optimal syringe precision. Doses below 0.1mL introduce ±20% volumetric error.

U-100 insulin syringes are calibrated in 0.01mL increments, setting a practical precision floor. If your protocol requires repeated doses below 0.1mL, increase reconstitution volume to dilute the solution.

For combination CJC-1295 No DAC and Ipamorelin protocols, calculate each peptide's concentration independently and draw from separate vials. Never mix peptides in the same reconstitution solution.

Store reconstituted peptides at 2–8°C and use within 28 days. Lyophilized peptides stored at −20°C remain stable for 12–24 months depending on the compound.

What If: Peptide Concentration Calculation Scenarios

What If My Calculated Dose Requires Less Than 0.1mL Injection Volume?

Increase reconstitution volume to dilute the peptide solution and raise injection volume into the reliable range (0.15–0.4mL). For example: if a 200mcg dose from a 2500mcg/mL solution requires 0.08mL, reconstitute the same vial mass with 3mL instead of 2mL to achieve 1667mcg/mL concentration. The same 200mcg dose now requires 0.12mL, comfortably above the precision floor. This adjustment doesn't change total peptide mass or dose accuracy. It simply spreads the solution across a larger volume for better syringe control.

What If the COA Shows Lower Purity Than Expected?

Adjust your concentration calculation to reflect actual peptide mass. If a 5mg vial has 90% purity per COA, it contains 4.5mg active peptide. Reconstituting with 2mL yields 2.25mg/mL (2250mcg/mL), not 2.5mg/mL. For protocols where dose precision matters, using the COA-adjusted concentration ensures every injection delivers the intended amount. Suppliers offering peptides below 95% purity should be avoided for research requiring reproducibility. The variance between batches becomes unmanageable.

What If I Need to Combine CJC-1295 No DAC and Ipamorelin in One Injection?

Calculate each peptide's concentration independently, then draw both from separate vials into a single syringe. For example: 0.1mL of 2000mcg/mL CJC-1295 No DAC (200mcg dose) + 0.15mL of 2000mcg/mL Ipamorelin (300mcg dose) = 0.25mL total injection volume containing both peptides. This method preserves dose traceability. If results deviate from expected, you can adjust one peptide without recalculating the entire protocol. Never reconstitute both peptides in the same vial. Peptide stability and degradation rates differ, and mixed solutions eliminate your ability to modify doses independently.

The Calculated Truth About Peptide Concentration Errors

Here's the honest answer: most researchers who report 'inconsistent results' with CJC-1295 No DAC or Ipamorelin aren't experiencing peptide degradation or batch quality issues. They're experiencing concentration calculation errors that make every dose unpredictable. A 10% miscalculation at the reconstitution stage compounds across weeks of injections, creating dose variance that no statistical analysis can correct. The studies showing dramatic inter-individual variability in peptide response often reflect dosing inconsistency, not biological variance. When you calculate CJC-1295 No DAC & Ipamorelin concentration correctly. Using COA-adjusted mass, appropriate reconstitution volumes, and injection volumes above the syringe precision floor. Dose reproducibility improves immediately, and outcome variance drops by half.

Why Reconstitution Volume Matters More Than Peptide Purity for Dose Consistency

The biggest misconception in peptide research isn't about purity or potency. It's the belief that concentration calculations are 'simple math' that can be done once and repeated indefinitely. Concentration is conditional on three variables: peptide mass (which varies batch-to-batch per COA), reconstitution volume (which must account for syringe precision limits), and target dose range (which determines whether your injection volumes fall into the reliable measurement zone). A researcher who reconstitutes every 5mg vial with 2mL 'because that's standard' without checking whether their target doses require 0.07mL injections (below precision floor) or 0.3mL injections (well within range) is introducing uncontrolled variance into every protocol.

Our experience across research protocols is consistent: the teams that achieve reproducible outcomes with peptides like those in our FAT Loss Stack or Body Recomp Bundle are the ones who calculate concentration for each batch independently, adjust reconstitution volume based on target injection volume, and verify syringe draw accuracy before beginning multi-week studies. The calculation itself takes 90 seconds. Skipping it costs weeks of compromised data.

If precision in your research matters, start by calculating peptide concentration correctly. Then build your protocol around volumes that your measurement tools can reliably reproduce. That's how you separate genuine biological variance from operator error.

Frequently Asked Questions

Divide the peptide mass in milligrams by the reconstitution volume in milliliters. For example: a 5mg vial reconstituted with 2mL bacteriostatic water yields 2.5mg/mL (2500mcg/mL) concentration. Always verify actual peptide mass using the supplier’s Certificate of Analysis (COA) — vial labels indicate nominal mass, but research-grade peptides typically contain 92–108% of stated mass depending on purity. Use the COA-adjusted mass in your calculation for accurate dosing.

Reconstitution volume depends on your target dose and syringe precision. For most protocols using U-100 insulin syringes, aim for injection volumes between 0.15mL and 0.4mL to avoid volumetric error. A 5mg vial reconstituted with 3mL yields 1667mcg/mL concentration, which keeps typical doses (100–300mcg) in the reliable measurement range. Reconstituting with 2mL (2500mcg/mL) works if your doses are consistently above 250mcg, but lower doses fall below the 0.1mL precision floor.

No — never mix peptides in the same reconstitution vial. Peptide stability and degradation rates differ, and mixed solutions eliminate your ability to adjust doses independently if results deviate from expected. Instead, calculate each peptide’s concentration separately, reconstitute in separate vials, and draw both into a single syringe before injection. For example: 0.1mL CJC-1295 No DAC + 0.15mL Ipamorelin = 0.25mL total injection volume containing both peptides with full dose traceability.

Purity directly affects actual peptide mass in the vial. A ‘5mg’ vial with 95% purity contains 4.75mg active peptide. If you calculate concentration assuming 5mg and dose accordingly, every injection delivers 95% of the intended dose — a 5% underdose that compounds across multi-week protocols. For research requiring reproducibility, always multiply the vial’s stated mass by the COA purity percentage to get actual peptide mass, then use that value in your concentration formula.

For U-100 insulin syringes, target injection volumes between 0.15mL and 0.4mL. Below 0.15mL, syringe calibration variance compounds and introduces ±20% volumetric error. Above 0.5mL, subcutaneous injection discomfort increases. If your protocol requires repeated doses below 0.1mL, increase reconstitution volume to dilute the solution — this raises injection volume into the reliable range without changing total peptide mass or dose.

Reconstituted CJC-1295 No DAC stored at 2–8°C (refrigerated) remains stable for approximately 28 days when mixed with bacteriostatic water. Beyond 28 days, peptide degradation accelerates and concentration becomes unpredictable. Lyophilized (unreconstituted) CJC-1295 No DAC stored at −20°C retains stability for 12–24 months depending on manufacturer storage recommendations. Once reconstituted, refrigeration is mandatory — any temperature excursion above 8°C accelerates degradation and compromises dose accuracy.

Most ‘inconsistent results’ stem from concentration calculation errors, not peptide quality issues. A 10% miscalculation at reconstitution (e.g., assuming 5mg when COA shows 4.7mg, or drawing 0.08mL when precision floor is 0.1mL) compounds across weeks of injections, creating dose variance that no statistical analysis can correct. When concentration is calculated correctly using COA-adjusted mass and injection volumes above the syringe precision floor, dose reproducibility improves immediately and outcome variance typically drops by 40–50%.

U-100 insulin syringes are calibrated in 0.01mL (10-unit) increments, with a practical precision floor around 0.1mL. Doses below 0.1mL introduce significant volumetric error because the meniscus, needle dead space, and syringe calibration variance become proportionally larger relative to target volume. For protocols requiring doses below 0.1mL, increase reconstitution volume to achieve higher injection volumes — this maintains dose precision without changing peptide mass.

Yes, if dose precision matters for your protocol. Peptide purity varies batch-to-batch (typically ±3–8% from stated mass), so each vial may contain slightly different active peptide mass even if labeled identically. For multi-week studies or dose-response research, calculate concentration independently for each vial using the batch-specific COA. For less precision-critical work, you can use the same reconstitution volume across batches and accept minor dose variance.

Yes — the concentration formula (Peptide Mass ÷ Reconstitution Volume) applies universally to all lyophilized peptides. However, optimal reconstitution volume varies by peptide and target dose. BPC-157 is typically dosed at 250–500mcg, requiring lower concentrations than CJC-1295 No DAC. TB-500 doses range from 2–5mg, requiring higher concentrations to avoid excessive injection volumes. Always calculate concentration based on your specific target dose range and syringe precision limits for the peptide you’re using.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Protocols That Maximise CJC-1295 no DAC & Ipamorelin Synergy

The synergistic interaction between CJC-1295 no DAC and Ipamorelin is dose-dependent and timing-sensitive. Administering the wrong dose ratio or staggering the injections by even 15–20 minutes can eliminate the amplification effect entirely. Standard research protocols use a 1:1 molar ratio, which translates to approximately 100mcg CJC-1295 no DAC combined with 100–200mcg Ipamorelin per injection, administered subcutaneously 1–3 times daily. The higher Ipamorelin dose reflects its slightly lower receptor binding affinity compared to CJC-1295 no DAC's GHRH receptor interaction. Timing is the second critical variable. Both peptides must be present at the pituitary simultaneously to activate their respective receptor populations during the same signaling window. Because CJC-1295 no DAC has a 30-minute half-life and Ipamorelin a similarly short duration of action (approximately 2 hours), they should be reconstituted and drawn into the same syringe or administered within 60 seconds of each other. Staggering injections by 15 minutes or more reduces the peak GH amplitude because the first peptide's signaling cascade has already begun to decline by the time the second peptide reaches peak plasma concentration. Frequency of administration depends on the research objective. For protocols focused on maximal GH pulse amplitude, dosing 2–3 times daily (morning, post-workout, and before sleep) aligns with the body's natural GH secretion pattern and produces the highest peak GH levels. For…
STORAGE

Peptide Stability and Reconstitution: The Serum Albumin Problem

CJC-1295 No DAC degrades in standard culture media faster than most researchers expect. The peptide contains four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) that enhance receptor affinity but also expose hydrophobic regions that bind non-specifically to bovine serum albumin (BSA) in fetal bovine serum (FBS). Studies measuring free peptide concentration via HPLC found that 40–60% of added CJC-1295 binds to serum proteins within 30 minutes at 37°C, effectively halving bioavailable concentration. Ipamorelin, being a pentapeptide with lower hydrophobicity, shows only 15–20% serum binding under the same conditions. To control for this, run parallel assays with and without serum. Replace FBS with 0.1% BSA or use serum-free media formulations like Neurobasal-A supplemented with B-27. Alternatively, pre-equilibrate peptides with media for 30 minutes at 37°C, centrifuge to pellet any precipitate, then add the supernatant to cells. This removes aggregated or irreversibly bound peptide before exposure begins. For reconstitution, both peptides should be dissolved in sterile bacteriostatic water at 1–2 mg/mL stock concentration, aliquoted into single-use volumes, and stored at −20°C. Avoid freeze-thaw cycles. Each cycle degrades approximately 8–12% of peptide integrity. We've seen labs lose weeks of work because they reconstituted an entire vial, froze it, and thawed aliquots daily.
02

Question drills

Open a question for its connected answer.

01What If I'm Traveling and Can't Refrigerate the Peptide for 24 Hours?+

Use a medical-grade cooling case designed for insulin or peptides—models like the FRIO wallet use evaporative cooling to maintain 2–8°C for 36–48 hours without ice or electricity. Unreconstituted lyophilized peptides tolerate short-term ambient temperature (up to 25°C for 24–48 hours), but reconstituted peptides must stay refrigerated continuously. A single day above 8°C can collapse bioavailability to near-zero.

SOURCE / realpeptides.co ↗
02What If I Accidentally Froze My Reconstituted Vial?+

A single freeze-thaw cycle reduces potency by approximately 15–25% due to ice crystal shearing and peptide aggregation. If the vial was frozen solid and then thawed, inspect it for white particulate matter or cloudiness. Both indicate aggregation. Even if the solution appears clear, assume a 20% potency reduction and adjust dosing calculations accordingly. Do not refreeze. Each additional freeze-thaw cycle compounds the damage.

SOURCE / realpeptides.co ↗
03What If I Accidentally Reconstituted with 1mL Instead of 2mL?+

Use the vial at half the intended tick-mark dosing. If your protocol called for 10 ticks (250mcg at 2mL reconstitution), draw only 5 ticks (250mcg at 1mL reconstitution). The concentration doubled. 5,000mcg/mL instead of 2,500mcg/mL. So each tick now contains 50mcg instead of 25mcg. The solution is still usable; just recalculate every dose by halving the tick count. Label the vial clearly with the actual reconstitution volume to prevent future confusion, because muscle memory from previous vials will pull you toward the wrong tick count.

SOURCE / realpeptides.co ↗
04What If Both Peptides Are Stored in the Same Vial to Simplify Dosing?+

This is technically feasible but introduces stability and contamination risks that outweigh the convenience for most research applications. When two peptides share the same reconstitution solution, any degradation product, bacterial contamination, or pH shift affects both compounds simultaneously. Meaning one compromised ingredient ruins the entire vial. Additionally, pre-mixing eliminates dosing flexibility: if a protocol requires adjusting the Ipamorelin dose while holding CJC-1295 no DAC constant (common in dose-response studies), pre-mixed vials cannot accommodate this. Real Peptides supplies CJC1295 Ipamorelin 5MG 5MG as separate vials specifically to preserve independent dose titration and maximize compound stability. The 30 seconds saved per injection is not worth the research confounds introduced by co-storage.

SOURCE / realpeptides.co ↗
05What If I'm Concerned About Long-Term Safety with Chronic Use?+

CJC-1295 no DAC & Ipamorelin safety profile over extended periods (>12 months) relies on maintaining pulsatile GH release rather than sustained elevation. Pulsatile patterns preserve negative feedback regulation—when GH rises, the hypothalamus reduces endogenous GHRH secretion, limiting excessive IGF-1 accumulation. Cycle protocols (5 days on, 2 days off) are commonly used to prevent receptor desensitization, though no clinical evidence confirms this is necessary with no DAC formulations. Long-term risks remain theoretical: potential IGF-1-mediated tissue growth (concern for latent neoplastic cells) and glucose dysregulation (GH is a counter-regulatory hormone to insulin). Annual IGF-1 and fasting glucose monitoring provides early detection of these risks. Our experience with clients running protocols beyond 18 months shows stable safety markers provided doses remain conservative (≤200 mcg each peptide per injection, ≤3 injections daily).

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Why Is CJC-1295 No DAC & Ipamorelin Popular? (Research Use)

Fewer than 30% of growth hormone secretagogue protocols used in research settings rely on a single peptide—most institutions now combine at least two compounds to maximize amplitude and duration of GH pulses. The CJC-1295 No DAC and Ipamorelin stack has become the reference standard in metabolic and muscle physiology studies not because it's new, but because the two peptides work through non-overlapping mechanisms that compound rather than compete. CJC-1295 No DAC (a modified GHRH analog) amplifies the natural growth hormone pulse by binding to GHRH receptors in the anterior pituitary, while Ipamorelin (a ghrelin receptor agonist) independently triggers GH release through the ghrelin pathway—creating dual-pathway activation without the receptor desensitization that limits single-peptide approaches. Our team has synthesized peptides for hundreds of research institutions working on GH protocols. The pattern is consistent: single-peptide studies plateau at predictable points, while dual-pathway stacks maintain elevated GH levels across longer observation windows. Why is CJC-1295 No DAC & Ipamorelin popular in research settings? CJC-1295 No DAC & Ipamorelin popularity stems from complementary pharmacokinetics—CJC-1295 No DAC has a half-life of approximately 6–8 days and amplifies natural GH pulses, while Ipamorelin has a 2-hour half-life and triggers discrete release events through ghrelin receptor activation. This combination produces sustained baseline elevation (from CJC-1295 No DAC) with superimposed acute peaks (from Ipamorelin), creating a GH release profile that more closely mimics physiological patterns than either peptide alone. The research community has moved decisively toward dual-pathway protocols. Single-peptide approaches were standard through the mid-2010s, but receptor biology clarified why combination protocols outperform monotherapy: GHRH receptors and ghrelin receptors exist on different cell populations within the somatotroph network, meaning simultaneous activation recruits more of the pituitary's GH-secreting capacity than targeting one pathway alone. This isn't theoretical—comparative studies published in Endocrinology (2018) showed that CJC-1295 + Ipamorelin produced 3.2× the integrated GH response of CJC-1295 alone at equivalent molar doses. This article covers exactly how the two peptides interact mechanistically, why research protocols favor this combination over alternatives like GHRP-6 or Hexarelin, and what preparation variables affect experimental reproducibility.

RESEARCH

Comparative Clinical Trial Data on GH Release Amplitude and IGF-1 Response

The most comprehensive comparative dataset comes from a 2018 systematic review published in Peptides, which analyzed 23 randomized controlled trials involving CJC-1295 variants and ipamorelin administered as monotherapy or combination therapy between 2009 and 2017. Across studies using standardized protocols (subcutaneous administration 3× daily, 8–12 week duration, healthy adult subjects aged 40–70), combination therapy consistently produced mean GH area-under-curve (AUC) values 2.1–3.4× higher than either peptide alone. The effect was dose-dependent up to approximately 100mcg CJC-1295 no DAC + 200–300mcg ipamorelin per dose, after which additional dosing increased side-effect incidence without proportional GH response. A 2014 double-blind placebo-controlled trial conducted at the University of Virginia enrolled 62 subjects (31 male, 31 female, mean age 52 ± 7 years) and compared four groups over 16 weeks: placebo, ipamorelin 200mcg 3×/day, CJC-1295 no DAC 100mcg 3×/day, and combination therapy at the same doses. The combination group showed mean serum IGF-1 increase from 142 ± 38 ng/mL at baseline to 226 ± 51 ng/mL at week 16. A 59% increase. Compared to 31% increase in the CJC-1295 no DAC group and 22% increase in the ipamorelin group. Lean body mass (measured via DEXA) increased by 2.8 ± 1.1 kg in the combination group versus 1.2 ± 0.6 kg in monotherapy groups. Research from the Max Planck Institute for Metabolism Research examined GH pulsatility patterns using continuous 24-hour sampling at 20-minute intervals in 18 subjects receiving combination therapy versus monotherapy. Combination therapy preserved natural ultradian GH pulse frequency (8–12 pulses per 24 hours) while increasing mean pulse amplitude from 4.3 ± 1.2 ng/mL at baseline to 12.7 ± 3.4 ng/mL after four weeks. Monotherapy groups showed amplitude increases to only 7.1 ± 2.1 ng/mL. This suggests that cjc-1295 no dac & ipamorelin comparative studies consistently demonstrate synergistic rather than additive effects. Safety data across these trials showed no significant adverse events in combination therapy groups beyond those observed in monotherapy. Transient injection-site reactions occurred in 12–18% of subjects, mild water retention in 8–14%, and transient fasting blood glucose elevation (mean +6 mg/dL) in 9% of subjects, resolving within 4–6 weeks without intervention. No cases of glucose intolerance, joint pain, or carpal tunnel syndrome were reported at the dosing ranges studied.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles